News Releases
by Year
2015
Dec. 01, 2015 (PDF/101KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Nov. 10, 2015 (PDF/187KB) Products
Received the Award for the First Time with the Pen-Style Medical Injector. A Unique Injector, "Ateos" for "Trulicity" Type 2 Diabetes Treatment Received "Good Design Gold Award."
Oct. 28, 2015 (PDF/316KB) Finances
Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2016
Oct. 28, 2015 (PDF/298KB) Finances
Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2016 [Japanese GAAP] (Unaudited)
Oct. 23, 2015 (PDF/144KB) Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the Half-Year Ended September 30, 2015
Oct. 01, 2015 (PDF/72KB) Corporate
Sumitomo Dainippon Pharma Celebrates 10th Anniversary of the Merger
Sep. 30, 2015 (PDF/152KB) Products
"Ateos" Injector for "Trulicity" Type 2 Diabetes Treatment Wins "Good Design Award 2015" and Selected as One of Good "Design Best 100 2015"
Sep. 16, 2015 (PDF/183KB) Products
Market Release of "Trulicity Subcutaneous Injection 0.75mg Ateos"Once-Weekly Type 2 Diabetes Treatment ： GLP-1 Receptor Agonist
Sep. 01, 2015 (PDF/54KB) Corporate
Sumitomo Dainippon Pharma announces personnel change
Aug. 28, 2015 (PDF/184KB) Products
Sunovion Announces FDA Approval of a New Indication for Aptiom (eslicarbazepine acetate) as Monotherapy for Partial-Onset Seizures
Jul. 29, 2015 (PDF/309KB) Finances
Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2016
Jul. 29, 2015 (PDF/152KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2016 [Japanese GAAP] (Unaudited)
Jul. 24, 2015 (PDF/223KB) R&D
Sumitomo Dainippon Pharma,CiRA and Hitachi Start Joint Research on Development of Key Evaluation Technologies: Evaluation for Industrialization in the Field of Regenerative Medicine -Toward Application of Human iPS Cell for Parkinson's Disease Treatment-
Jul. 15, 2015 (PDF/122KB) Licensing
Sumitomo Dainippon Pharma Announces Commercialization Partnership with Servier on Its Atypical Antipsychotic Agent Latuda (lurasidone hydrochloride) for Australia
Jul. 09, 2015 (PDF/66KB) Licensing
Eli Lilly Japan and Sumitomo Dainippon Pharma signed a sales collaboration agreement for a once-weekly GLP-1 receptor agonist "Trulicity Subcutaneous Injection 0.75 mg Ateos"
Jul. 01, 2015 (PDF/57KB) Corporate
Sumitomo Dainippon Pharma announces Changes in Executive Officers and Other Key Positions
Jun. 17, 2015 (PDF/89KB) R&D
JCR and Sumitomo Dainippon Pharma Conclude a Feasibility Study Agreement on Application of the Blood-Brain Barrier Penetration Technology in Psychiatry and Neurology Area
Jun. 01, 2015 (PDF/329KB) R&D
Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types
May 20, 2015 (PDF/117KB) Products
Toray Receives Japanese Approval for Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 μg and Promotion to Start
May 19, 2015 (PDF/195KB) R&D
Sunovion Pharmaceuticals Inc. Announces Positive Results for Latuda (lurasidone HCl) in First Placebo-Controlled Trial of Patients with Major Depressive Disorder with Mixed (Subsyndromal Hypomanic) Features
May 13, 2015 (PDF/353KB) R&D
Boston Biomedical to Highlight Data Examining Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types at ASCO 2015
May 11, 2015 (PDF/321KB) Finances
Supplementary Financial Data for the Year Ended March 31, 2015
May 11, 2015 (PDF/1,023KB) Finances
Summary of Consolidated Financial Results for the Year Ended March 31, 2015 [Japanese GAAP] (Unaudited)
May 07, 2015 (PDF/291KB) Licensing
Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate their Agreement for the Joint Development and Exclusive Commercialization of Latuda (lurasidone) - an Atypical Antipsychotic Agent, in Europe
Apr. 24, 2015 (PDF/179KB) R&D
Sumitomo Dainippon Pharma Makes a Follow-up Announcement on the Preliminary Findings from a Phase III Clinical Study (PASTEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
Apr. 24, 2015 (PDF/130KB) Corporate
Sumitomo Dainippon Pharma Revises Its Basic Policy on Internal Control System
Mar. 20, 2015 (PDF/41KB) Corporate
Sumitomo Dainippon Pharma announces personnel changes
Mar. 03, 2015 (PDF/114KB) Products
Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 μg and Notice Regarding Promotion Tie-up
Mar. 02, 2015 (PDF/119KB) Corporate
Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
Feb. 26, 2015 (PDF/326KB) R&D
Sunovion Pharmaceuticals Inc. Announces Initiation of Phase 3 Clinical Trial Program for SUN-101/eFlow® (Glycopyrrolate) in Moderate-to-Very SevereChronic Obstructive Pulmonary Disease (COPD)
Jan. 29, 2015 (PDF/308KB) Finances
Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2015
Jan. 29, 2015 (PDF/155KB) Finances
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2015 [Japanese GAAP] (Unaudited)
Jan. 29, 2015 (PDF/108KB) Licensing
Sumitomo Dainippon Pharma Announces Collaboration on Lurasidone, an Atypical Antipsychotic Agent, for Thailand, Singapore and Hong Kong
Jan. 14, 2015 (PDF/165KB) Corporate
Sunovion Pharmaceuticals Inc. Files Patent Infringement Lawsuits Regarding Latuda
Jan. 07, 2015 (PDF/196KB) R&D
Sunovion Pharmaceuticals Inc. Announces FDA Acceptance for Review of Supplemental New Drug Application for the Use of Aptiom (eslicarbazepine acetate) as Monotherapy Treatment for Partial Onset Seizures